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Abstract
Introduction This study sought to assess the prognostic value
of the kinetics of procalcitonin (PCT), C-reactive protein (CRP)
and clinical scores (clinical pulmonary infection score (CPIS),
Sequential Organ Failure Assessment (SOFA)) in the outcome
of ventilator-associated pneumonia (VAP) at an early time point,
when adequacy of antimicrobial treatment is evaluated.
Methods This prospective observational cohort study was
conducted in a teaching hospital. The subjects were 75 patients
consecutively admitted to the intensive care unit from October
2003 to August 2005 who developed VAP. Patients were
followed for 28 days after the diagnosis, when they were
considered survivors. Patients who died before the 28th day
were non-survivors. There were no interventions.
Results PCT, CRP and SOFA score were determined on day 0
and day 4. Variables included in the univariable logistic
regression model for survival were age, Acute Physiology and
Chronic Health Evaluation (APACHE) II score, decreasing
∆SOFA, decreasing ∆PCT and decreasing ∆CRP. Survival was
directly related to decreasing ∆PCT with odds ratio (OR) = 5.67
(95% confidence interval 1.78 to 18.03), decreasing ∆CRP with
OR = 3.78 (1.24 to 11.50), decreasing ∆SOFA with OR = 3.08
(1.02 to 9.26) and APACHE II score with OR = 0.92 (0.86 to
0.99). In a multivariable logistic regression model for survival,
only decreasing ∆PCT with OR = 4.43 (1.08 to 18.18) and
decreasing ∆CRP with OR = 7.40 (1.58 to 34.73) remained
significant. Decreasing ∆CPIS was not related to survival (p =
0.59). There was a trend to correlate adequacy to survival. Fifty
percent of the 20 patients treated with inadequate antibiotics
and 65.5% of the 55 patients on adequate antibiotics survived
(p = 0.29).
Conclusion Measurement of PCT and CRP at onset and on the
fourth day of treatment can predict survival of VAP patients. A
decrease in either one of these marker values predicts survival.
Introduction
Ventilator-associated pneumonia (VAP) is defined as pneumo-
nia occurring more than 48 hours after endotracheal intubation
and the initiation of mechanical ventilation. When a clinical
diagnosis of VAP is suggested by a new or progressive pulmo-
nary infiltrate associated with fever, an increased white blood
cell count and purulent tracheobronchial secretion [1,2],
efforts directed towards the achievement of a microbial diag-
nosis of VAP by invasive or non-invasive techniques are justi-
fied [3].
The mortality rate for VAP ranges from 24% to 50% and can
reach 76% in some specific settings or when lung infection is
caused by high-risk pathogens [4]. A body of evidence shows
that inadequate antimicrobial treatment is an important deter-
minant of mortality [5-8]. Adequacy of antimicrobial therapy is
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usually assessed on the third day of treatment, on the basis of
clinical parameters and microbiological identification.
Markers of the inflammatory response and their kinetics have
been studied in the prediction of outcomes in sepsis [9,10]
and VAP [11]. In particular, procalcitonin (PCT) has been eval-
uated as a marker of sepsis and infection. Severe generalized
bacterial infections with systemic manifestations are associ-
ated with increased serum levels of PCT. In contrast, viral
infections, localized bacterial infections, or inflammatory reac-
tions of non-infectious origin do not, or only moderately,
increase PCT levels [12,13]. Some studies describe PCT as a
predictor of severity in sepsis, antimicrobial efficiency and hos-
pital mortality [14-17]. Differential diagnosis and antibiotic
treatment as well can be improved by using this marker
[18,19].
Considering the variability of PCT levels, it is possible to theo-
rize that increasing levels, more than a high livel at onset, may
indicate persistent infection activity, whereas decreasing val-
ues suggest resolution. We undertook a study to assess the
prognostic value of the kinetics of PCT, C-reactive protein
(CRP), and the clinical scores clinical pulmonary infection
score (CPIS) [20], Sequential Organ Failure Assessment
(SOFA) [21], and Acute Physiology and Chronic Health Eval-
uation (APACHE) II [22], in the outcome of VAP at an early
time point, when adequacy of antimicrobial treatment is
evaluated.
Materials and methods
The study was conducted in the clinical/surgical 26-bed inten-
sive care unit (ICU) of the Hospital de Clínicas de Porto Alegre
(HCPA), a tertiary-care–teaching institution with 744 hospital
beds.
All patients consecutively admitted to the ICU suspected of
VAP were eligible for this prospective observational cohort
study. Patients at least 18 years old were recruited. Exclusion
criteria were a previous diagnosis of AIDS or neutropenia
below 500 cells/ml. Pneumonia was considered ventilator-
associated when it occurred after 48 hours of mechanical ven-
tilation and was judged to not have been incubating before
starting mechanical ventilation. VAP was considered early-
onset when it occurred during the first four days of mechanical
ventilation and late-onset when it developed five or more days
after the initiation of mechanical ventilation [23]. APACHE II
was calculated during the first 24 hours of admission to ICU.
Patients were considered immunosuppressed when they had
received chemotherapy within the preceding 45 days, or had
neutropenia of less than 1,000/mm3.
Diagnosis of pneumonia was suspected when a patient devel-
oped a new and persistent radiographic infiltrate plus two of
the following: (1) body temperature more than 38°C or less
than 36°C; (2) white blood cells more than 11,000 or less than
4,000/mm3  (3) macroscopically purulent tracheal aspirate
[24]. Purulent endotracheal aspirate was defined on inspec-
tion by the assistant team. The axillary temperature used was
the highest in the previous 24 hours before the inclusion on
the study.
Chest X-ray, arterial blood gases, complete blood count, cre-
atinine, total bilirubin, albumin, PCT and CRP were obtained
by the that time VAP was suspected (D0) and repeated on the
fourth day of treatment (D4). Quantitative endotracheal aspi-
rate (QEA) was obtained on D0, repeated on the third day
after the diagnosis (D3) and then weekly. Sterile endotracheal
aspirates were obtained with a suction catheter adapted to a
mucus collector without saline instillation, and two samples of
hemocultures were collected from different veins with a 15-
minute interval before starting antimicrobial treatment.
CPIS [25], modified as described by Singh and colleagues
[20], was calculated on the basis of data on D0 and D3.
Patients were assumed to have VAP when the CPIS was 7
points or more. CPIS was calculated with data from D0, add-
ing points for microbiological results and progression of pul-
monary infiltrate on a new chest X-ray on D3. To calculate
CPIS on D3, data from D3 were used to study the kinetics of
the modified CPIS.
For a diagnosis of VAP, there should be no evidence of
another medical condition to which the presenting symptoms,
signs or radiological findings could be attributed. A SOFA
score was calculated on D0 and D4. QEA was considered
positive when values were at least 105 colony-forming units/
ml.
All patients with a clinical suspicion of VAP, later confirmed by
a CPIS of at least 7 and fulfilling inclusion criteria, were
included and received empirical antimicrobial therapy on D0.
The choice of antibiotics and changes rested solely with the
critical care team or primary service caring for the patient.
Modifications to empirical therapy were based on the results
of QEA and hemocultures. Mechanical ventilation, physiother-
apy and airway management were performed in accordance
with a standard protocol in all patients.
Patients' progress was followed until the 28th day (D28) after
the diagnosis of VAP, when they were considered survivors.
Patients who died before D28 were non-survivors. Patients
discharged from the ICU before D28 were also considered
survivors. All patients with VAP were reviewed by one of the
investigators to confirm the diagnosis on the basis of predeter-
mined criteria.
Seventy-five patients were enrolled from October 2003 to
August 2005 and constituted the study population. The
research protocol was reviewed and approved by the Human
Research Committee from the HCPA, and informed writtenAvailable online http://ccforum.com/content/10/5/R125
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consent was obtained from patients' representatives before
enrollment. The study protocol conforms to the ethical guide-
lines of the Declaration of Helsinki.
Trained investigators collected data on D0, D3, D4, and
weekly until D28. Recorded data included age, sex, cause of
ICU admission, arterial partial pressure of oxygen/fraction of
inspired oxygen (PaO2/FiO2), APACHE II score, SOFA score,
CPIS, co-morbidities including chronic obstructive pulmonary
disease, whether active smoker, history of congestive heart
failure, history of malignancy, immunosuppression, albumin,
use of histamine type-2 receptor (H2) antagonist, use of pro-
ton pump inhibitor, use of corticosteroids, dialysis, central vein
catheterization, urinary tract catheterization, duration of
mechanical ventilation, duration of stay in ICU before VAP, car-
diopulmonary resuscitation, intubation (orotracheal versus
nasotracheal), and tracheotomy.
Adequacy of the empirical antimicrobial treatment was
recorded on the basis of microbiological results. Adequate
antibiotic therapy was defined as coverage of all the patho-
gens isolated (from QEA culture or from blood), by at least one
antimicrobial administered by the onset of VAP, determined by
the sensitivity pattern in the antibiogram [26]. Treatment was
considered adequate when cultures were negative.
PCT was determined with the commercially available immuno-
luminometric assay (Brahms PCT LIA; Brahms Diagnostika,
Berlin, Germany) with an analytical sensitivity of 0.1 ng/ml and
analyzed with a Lumat LB 9507 Luminometer (Berthold, Bad
Wildbad, Germany). Blood was drawn when a diagnosis of
VAP was clinically suspected, before empirical antibiotic treat-
ment was started. Samples of serum were prepared and fro-
zen immediately after blood was drawn, then stored at -80°C
in the HCPA research laboratory. Assays were performed in
batches at the end of the study period.
CRP was measured by nephelometry (Bade Behring, Mar-
burg, Germany), routinely determined at the HCPA laboratory.
Kinetics definitions
Dichotomized ∆ was calculated by the formula ∆ = D4 - D0.
Therefore ∆PCT = PCTD4 - PCTD0, ∆CRP = CRPD4 - CRPD0,
and ∆SOFA = SOFAD4 - SOFAD0.
CPIS was calculated on D0 and D3. Consequently, ∆CPIS =
CPISD3 - CPISD0.
∆ > 0 means increasing values and ∆ ≤ 0 means decreasing
values.
Microbiological processing
Endotracheal samples were initially analyzed with Gram stain.
They were rejected if there were more than ten squamous epi-
thelial cells per low-power field (magnification × 100), requir-
ing a new sample [27]. Samples considered acceptable were
mixed in a 1:1 proportion with N-acetylcysteine, mechanically
liquefied and homogenized with a vortex mixer for two minutes.
After incubation for two hours at room temperature, samples
were again vortex-mixed for 30 s and serially diluted in sterile
0.9% saline solution to obtain final concentrations of 1:100
and 1:10,000. Aliquots of 0.1 ml were plated on chocolate
agar. Depending on the Gram stain results, samples also were
plated on sheep blood agar, azide blood agar or MacConkey
agar. All plates were incubated at 35°C overnight in a 5% car-
bon dioxide incubator, except for those in MacConkey agar,
which were incubated in normal atmosphere without carbon
dioxide. Isolates were assessed within 24 and 48 hours and
were characterized by colony morphology and Gram stain.
Microorganisms were identified by standardized laboratory
methods. For plates inoculated with 1:100 dilution, the pres-
ence of 5 colonies was considered to show 104, 50 colonies
105, and 500 colonies 106 colony-forming units/ml. In plates
inoculated with 1:10,000 dilution, the presence of 5 colonies
was considered to show 106 colony-forming units/ml.
Statistical analysis
Continuous baseline data are expressed as means ± SD. Cat-
egorical variables were compared with the χ2 test. Continuous
kinetics data are expressed as medians (range). ∆PCT, ∆CRP
and ∆SOFA were categorized as increasing or unchanged/
decreasing. The Kruskal–Wallis test was used to compare
groups for continuous variables. For these analyses, two-tailed
tests and p ≤ 0.05 were considered statistically significant.
Logistic regression analysis was used to determine the rela-
tion of risk factors to clinical outcome. In the multivariable
model we considered significant variables with biological
importance. Variables with p  < 0.20 in univariable logistic
regression were entered into the multivariable model. In the
multivariable model we considered as significant those varia-
bles with p < 0.05. SPSS 11.0 for Windows (SPSS Inc., Chi-
cago, IL, USA) was used for statistical analysis.
Results
Baseline characteristics at the inclusion of the 75 VAP
patients, stratified as survivors or non-survivors, are given in
Table 1. Microbiological identification in QEAs is shown in
Table 2.
Kinetic data on PCT and CRP from D0 to D4 are shown in Fig-
ure 1. PCT levels were lower in survivors on D0 (p = 0.003)
and on D4 (p = 0.001). PCT levels increased in non-survivors
but not in survivors (Table 3). Decreasing ∆PCT was not
related to adequacy of antibiotic treatment on the basis of
QEA results on D0 (p = 0.76). CRP levels showed no differ-
ence between survivors and non-survivors on D0 (p = 0.77)
and on D4 (p = 0.14). Decreasing ∆CRP was not related to
adequacy of antibiotic treatment based on QEA results on D0
(p = 0.13). CPIS did not discriminate survivors from non-survi-
vors on D0 (p = 0.32) or on D3 (p = 0.45). Decreasing ∆CPISCritical Care    Vol 10 No 5    Seligman et al.
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was not related to survival (p = 0.59); neither was CPIS < 6
on D3 (p = 0.79). Decreasing ∆CPIS and CPIS < 6 on D3
were not related to adequacy of antibiotic treatment (p = 1.00
and  p  = 0.55, respectively). Patie n t s  w h o  d i e d  b e f o r e  D 4
could not have kinetics determined and are classed as missing
cases. Fifteen patients were not included in the kinetics analy-
sis. Eight patients died and one patient left the ICU before D4.
Data on six patients were missing as a consequence of a logis-
tic flaw. The evolution of clinical scores and laboratory param-
eters are presented in Table 3.
Variables included in the univariable logistic regression model
for survival were age, APACHE II, decreasing ∆SOFA,
decreasing  ∆PCT, and decreasing ∆CRP. The results are
shown in Table 4. Survival was directly related to decreasing
∆PCT with odds ratio (OR) = 5.67 (95% confidence interval
1.78 to 18.03), p = 0.003; decreasing ∆CRP with OR = 3.78
(1.24 to 11.50), p = 0.02; decreasing ∆SOFA with OR = 3.08
(1.02 to 9.26), p = 0.05; and APACHE II score with OR =
0.92 (0.86 to 0.99), p = 0.02. Age was not significant, but p
= 0.10 was a reason for inclusion in the multivariable model.
Table 1
Baseline characteristics of 75 patients who developed ventilator-associated pneumonia
Parameter Survivors (n = 46) Non-survivors (n = 29) Total (n = 75) p
Age (years)a 58 ± 14) 64 ± 16 61 ± 15 0.09
APACHE II scorea 18 ± 6 22 ± 9 19 ± 7 0.02
Albumin level (mg/dl)a 2.8 ± 0.6 2.5 ± 0.5 2.7 ± 0.6 0.02
Male sex (percentage) 67.4 44.8 58.7 0.06
Origin (percentage) 0.23
Medical 52.2 69.0 58.7
Surgical 47.8 31.0 41.3
Onset (percentage)b 0.59
Early onset 21.7 27.6 24.0
Late onset 78.3 72.4 76.0
COPD (percentage) 17.4 27.6 21.3 0.39
Congestive heart failure (percentage) 17.4 27.6 21.3 0.39
Malignancy (percentage) 13.1 13.8 13.3 1.00
H2 antagonist (percentage) 67.4 55.2 62.7 0.33
Proton pump inhibitor (percentage) 21.7 37.9 28.0 0.19
Corticosteroids (percentage) 13.1 24.1 17.3 0.23
Dialysis (percentage) 10.9 17.3 13.3 0.50
Smoker (percentage) 37.8 44.8 40.5 0.63
Intubation (percentage) 0.39
Orotracheal 84.8 89.7 87.8
Nasotracheal 2.2 3.5 2.7
Tracheotomy 13.1 3.5 9.5
Septic status (percentage) 0.04
Sepsis 67.4 13.8 46.7
Severe sepsis 28.3 34.5 30.7
Septic shock 4.4 51.7 22.7
APACHE, Acute Physiology and Chronic Health Evaluation; COPD, chronic obstructive pulmonary disease. aResults are means ± SD. bEarly 
onset is defined as occurring during the first four days of mechanical ventilation, and late onset as occurring five or more days after mechanical 
ventilation.Available online http://ccforum.com/content/10/5/R125
Page 5 of 9
(page number not for citation purposes)
The multivariable logistic regression model for survival
included the variables from the univariable analysis. Only
decreasing ∆PCT with OR = 4.43 (1.08 to 18.18), p = 0.04,
and decreasing ∆CRP with OR = 7.40 (1.58 to 34.73), p =
0.01, remained significant (Table 4).
Adequacy of antimicrobial treatment based on microbiological
data of QEA on D0 did not discriminate survivors from non-
survivors (p = 0.29; Table 5).
The influence of septic status on the kinetics of PCT, CRP and
SOFA is shown in Table 6. Increasing ∆PCT was more fre-
quent than sepsis and severe sepsis in septic shock, and
decreasing  ∆PCT occurred more frequently in sepsis and
severe sepsis; however, these results were not statistically sig-
nificant (p = 0.12). There was no difference in the performance
of  ∆CRP (p  = 0.96) and ∆SOFA (p  = 0.97) in all three
statuses.
None of the patients included in the study achieved immuno-
suppression criteria. Only 17.3% of patients received corti-
costeroids, without statistical significance between survivors
and non-survivors (p  = 0.23) and corticosteroid dosage
between groups (p = 0.25).
Discussion
Our results showed that, on D0 and D4, PCT levels and SOFA
score differentiated survivors from non-survivors. Decreasing
values of CRP and decreasing values of PCT were able to pre-
dict, respectively, a sevenfold and fourfold greater chance for
patients with VAP to survive.
CRP is used as a parameter to support the diagnosis of infec-
tion [9]. Yentis and colleagues [10] demonstrated that a
decrease in CRP by 25% or more from the previous day's level
was a good indicator of resolution of sepsis, with a sensitivity
of 97%, a specificity of 95% and a predictive value of 97%.
The decrease in CRP preceded clinical resolution of sepsis
and was more likely to occur in patients with less severe sep-
sis than in those with severe sepsis or septic shock [10]. In our
results, absolute CRP levels could not differentiate survivors
from non-survivors on D0 and D4 (p = 0.77 and 0.14, respec-
tively). Nevertheless, similarly to the results of Yentis and col-
leagues in patients with sepsis, in our VAP patients the
Table 2
Microbiological identification and survival in quantitative endotracheal aspirate in 75 patients with ventilator-associated 
pneumonia
Microorganisms Survivors (n = 58) Non-survivors (n = 34) Total (n = 92)a
Pseudomonas aeruginosa 9 (15.5) 6 (17.7) 15 (16.3)
Oxacillin-resistant Staphylococcus aureus 8 (13.8) 6 (17.7) 14 (15.2)
Oxacillin-sensitive Staphylococcus aureus 7 (12.1) 1 (3.0) 8 (8.7)
Stenotrophomonas maltophilia 3 (5.2) 3 (8.8) 6 (6.5)
Acinetobacter sp. 4 (6.9) 1 (3.0) 5 (5.4)
Enterobacter sp. 4 (6.9) 1 (3.0) 5 (5.4)
Klebsiella pneumoniae 2 (3.5) 3 (8.8) 5 (5.4)
Haemophilus sp. 4 (6.9) 0 4 (4.4)
Escherichia coli 1 (1.7) 2 (5.9) 3 (3.3)
Citrobacter koseri 2 (3.5) 0 2 (2.2)
Proteus mirabilis 2 (3.5) 0 2 (2.2)
Other Gram-negative nonfermenting bacilli 1 (1.7) 0 1 (1.1)
Acinetobacter junii 1 (1.7) 0 1 (1.1)
Streptococcus agalactiae 1 (1.7) 0 1 (1.1)
Serratia sp. 1 (1.7) 0 1 (1.1)
Moraxella sp. 1 (1.7) 0 1 (1.1)
Streptoccocus pneumoniae 1 (1.7) 0 1 (1.1)
Burkholderia cepacea 0 1 (3.0) 1 (1.1)
Unidentified 6 (10.4) 10 (29.4) 16 (17.4)
a In 17 patients more than one microorganism was identified.
Quantitative endotracheal aspirate was deemed positive when ≥105 colony-forming units/ml. Not all percentages add up to 100 because of 
rounding. Results are given as frequency (percentage).Critical Care    Vol 10 No 5    Seligman et al.
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decrease of CRP levels was significantly predictive of survival,
with OR = 7.40.
We assessed the correlation of CPIS changes from D0 to D3
with survival. The kinetics of CPIS from D0 to D3 was chosen
to compare with published data. Luna and colleagues [26]
studied 63 patients with clinical evidence of VAP and bacteri-
ologic confirmation by bronchoalveolar lavage or blood cul-
tures. In their sample, CPIS fell progressively in the population
as a whole, and the decrease in CPIS was significant in survi-
vors but not in non-survivors. When CPIS was less than 6 at 3
or 5 days after VAP onset, mortality was lower than in the
remaining patients. They considered these differences to be
related to the finding that patients receiving adequate therapy
had a slight fall in CPIS, whereas those receiving inadequate
therapy did not. However, their mortality rate was not statisti-
cally significant: 69.2% for patients treated with inadequate
antibiotic treatment and 46.0% for patients on adequate anti-
biotic treatment (p = 0.238). Their mortality rate in all patients
was 50.8%. Those results are in partial contrast with ours. In
our sample, serial measurements of modified CPIS on D0 and
D3 could not differentiate between survivors and non-survi-
vors (p = 0.44 for D0; p = 0.43 for D3). We could not correlate
decreasing ∆CPIS with survival (p = 0.79); CPIS < 6 on D3
was also not correlated with survival (p = 0.59).
We assessed the possible correlation of changes in CPIS
from D0 to D3 with adequacy of antibiotic treatment on the
basis of microbiological results of QEA on D0. We could not
correlate decreasing ∆CPIS with adequacy of antibiotic treat-
ment (p = 1.00) and CPIS < 6 on D3 with adequacy of treat-
ment (p = 0.55). Neither decreasing ∆PCT and ∆CRP was
related to adequacy of antibiotic treatment on the basis of
QEA results on D0 in our sample. We also could not correlate
survival with adequacy of antibiotic treatment: 50.0% of the 20
patients treated with inadequate antibiotics survived, and
65.5% of the 55 patients on adequate antibiotics survived (p
= 0.29). There was a trend to correlate adequacy with survival,
but the lack of statistical significance may represent a type 2
error.
Multiple organ dysfunction syndrome is associated with mor-
tality. Vincent and colleagues [21] demonstrated that multiple
organ dysfunction and high SOFA scores for any individual
organ were associated with increased mortality. In their sam-
ple, the SOFA score increased in 44% of the non-survivors but
in only 20% of the survivors (p < 0.001) in patients who stayed
at least 1 week in the ICU. Our results with SOFA score were
similar to those: the SOFA score was higher in non-survivors
on D0 (p = 0.002) and D4 (p = 0.002; Table 3) and decreas-
ing SOFA scores were predictive of survival, with OR = 3.08
(p = 0.05) in the univariable, but not in the multivariable, logis-
tic regression (p = 0.54).
Figure 1
Kinetics of serum PCT (top) and CRP (bottom) in survivors and non- survivors Kinetics of serum PCT (top) and CRP (bottom) in survivors and non-
survivors. Box plots represent the 25th and 75th centiles; the internal 
horizontal line shows the median and whiskers show the 10th and 90th 
centiles. Circles represent outliers. Comparing between groups, p = 
0.003 in D0 and p < 0.001 in D4 for procalcitonin (PCT); p = 0.77 in 
D0 and p = 0.14 in D4 for C-reactive protein (CRP).Available online http://ccforum.com/content/10/5/R125
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In our results, PCT levels were significantly higher in non-sur-
vivors on D0 (p = 0.003) and D4 (p = <0.001). Furthermore,
the decrease in PCT levels was significantly predictive of sur-
vival, with OR = 4.43. Other studies on patients with VAP have
reported higher PCT levels in non-survivors than in survivors
[28,29]. In a study with children with severe bacterial infection,
Assicot and colleagues [12] reported that serum PCT values
decreased rapidly during antibiotic therapy.
We analyzed the influence of septic status on the kinetics of
PCT, CRP and SOFA. Increasing ∆PCT was more frequent in
patients with septic shock than in septic and severely septic
patients. There was a trend of more frequent decreasing ∆PCT
sepsis and severe sepsis, but these results were not statisti-
cally significant (p = 0.12) and may be attributed to sample
size. There was no difference in the performance of ∆CRP and
∆SOFA in all three statuses (p = 0.96 and p = 0.97, respec-
tively) in our sample.
Although high PCT levels at the onset of sepsis have been
reported to be associated with lethal outcome [30], this obser-
vation was not corroborated by Meisner and colleagues [14].
They compared PCT and CRP at different SOFA scores dur-
ing the course of sepsis and multiple organ dysfunction syn-
drome. Measurement of PCT during multiple organ
dysfunction syndrome provided more information about the
severity and the course of disease than that of CRP. Higher
SOFA scores were associated with significantly higher plasma
PCT concentrations, whereas CRP was elevated irrespective
of the scores observed. In a similar manner to our results, they
found an increase in PCT levels after day 4 in non-survivors (p
< 0.01). In that study, a rapid decline of PCT levels in patients
who recovered and survived was also observed, whereas CRP
increased for several days even after recovery and discharge
of the patient from the ICU.
Table 3
Evolution of clinical scores and laboratory parameters in patients with ventilator-associated pneumonia
Parameter Survivors (n = 45) Non-survivors (n = 23) p
Procalcitonin D0 0.58 (0.08–19.60) 2.18 (0.19–21.33) 0.003
Procalcitonin D4 0.30 (0.08–36.19) 3.44 (0.39–17.00) <0.001
C-reactive protein D0 160.0 (11.6–388.0) 167.5 (5.6–349.0) 0.77
C-reactive protein D4 108.0 (6.8–282.0) 148.0 (9.0–384.0) 0.14
SOFAD0 5 (0–12) 7 (2–20) 0.002
SOFAD4 4 (0–13) 7 (0–18) 0.002
CPISD0
a 8 (5–13) 8 (7–12) 0.32
CPISD3 6 (2–12) 7 (3–10) 0.45
Results are shown as median (range). D0, day of VAP diagnosis; D3, 3 days after VAP; D4, 4 days after VAP diagnosis; SOFA, Sequential Organ 
Failure Assessment; CPIS, modified clinical pulmonary infection score. aCPIS was calculated as described by Singh and colleagues.
Table 4
Odds ratios for survival in 75 patients with ventilator-associated pneumonia
Parameter Univariable Multivariable
OR (95% CI) p OR (95% CI) p
Age (years) 0.97 (0.84–1.01) 0.10 0.96 (0.91–1.01) 0.11
APACHE II score 0.92 (0.86–0.99) 0.02 0.91 (0.81–1.02) 0.09
∆SOFA decreasing values 3.08 (1.02–9.26) 0.05 2.25 (0.48–10.46) 0.30
∆CRP decreasing levels 3.78 (1.24–11.50) 0.02 7.40 (1.58–34.73) 0.01
∆PCT decreasing levels 5.67 (1.78–18.03) 0.003 4.43 (1.08–18.18) 0.04
The results show a univariable and multivariable logistic regression analysis of parameter kinetics. APACHE, Acute Physiology and Chronic Health 
Evaluation; SOFA, Sequential Organ Failure Assessment; CRP, C-reactive protein; PCT, procalcitonin; OR, odds ratio; CI, confidence interval.
Table 5
Cross-tabulation of adequacy of treatment with survival in 75 
patients with ventilator-associated pneumonia
Adequacy of 
treatment
Survivors (n = 46) Non-survivors
(n = 29)
Total
(n = 75)
p
Adequate 36 (78.3) 19 (62.1) 55 (72) 0.29
Inadequate 10 (21.7) 10 (37.9) 20 (28)
Results are numbers of patients; percentages are given in 
parentheses.Critical Care    Vol 10 No 5    Seligman et al.
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Changes in biological markers levels may indicate a modifica-
tion in clinical status. In a recent study, Luyt and colleagues
[11] assessed the value of PCT kinetics as a prognostic
marker during VAP in 63 patients, with measures on days 1, 3
and 7. Unfavorable outcomes were death, recurrence of VAP,
or occurrence of extrapulmonary infection requiring antibiotic
treatment during the first 28 days of VAP. PCT levels in the
sample generally decreased from D1 to D7 but increased in
patients with unfavorable outcome. For PCT analysis, the
study by Luyt and colleagues used the time-resolved amplified
cryptate emission technology, an expensive apparatus not
available worldwide. We analyzed PCT with a luminometry
assay, which is less expensive and commercially available.
This strategy has the inconvenience of being less sensitive
than the research technology, but it may offer a cost-effective
option. Our study design also had some distinctions: our main
outcome was survival and we assessed change in PCT over
four days, which may be clinically more relevant because this
is the time frame during which VAP treatment is frequently
reassessed [31].
Considering the mortality rate of VAP, it is highly desirable to
have early laboratory markers to predict survival or the neces-
sity to reassess initial empirical antimicrobial therapy. In our
sample, decreasing ∆SOFA, ∆PCT and ∆CRP were signifi-
cantly predictive of survival in univariable analysis, but the
multivariable regression model maintained only ∆PCT and
∆CRP as independent predictors for survival, as early as in D4.
Patients may express different serum levels of markers when
exposed to bacterial toxins, and this stimulation may be multi-
factorial. The advantage of kinetics was that, independently of
an absolute value, decreasing values were related to survival;
this outcome is suggestive of a decrease in stimulus to inflam-
mation and a decrease in exposure to bacterial toxins.
Conclusion
Measurement of PCT and CRP at onset and the fourth day of
treatment can predict the survival of patients with VAP. A
decrease in either of these marker values predicts survival. The
identification of those with good outcome as early as on day
four could possibly help to ensure the adequacy of antimicro-
bial therapy. Further studies with a larger sample are
necessary to establish whether a combination of marker kinet-
ics can be used to guide antimicrobial therapy, especially in
cases in which microorganisms are not identified.
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Table 6
Cross-tabulation of PCT, CRP and SOFA kinetics with septic status in patients with VAP
Kinetics Sepsis Severe sepsis Septic shock p
∆PCT ≤ 0 (n = 42) 23 (74.2) 14 (70.0) 5 (41.7)
∆PCT > 0 (n = 21) 8 (25.8) 6 (30.0) 7 (58.3)
Total (n = 63) 31 20 12 0.12
∆CRP ≤ 0 (n = 45) 22 (71.0) 15 (68.2) 8 (66.7)
∆CRP > 0 (n = 20) 9 (29.0) 7 (31.8) 4 (33.3)
Total (n = 65) 31 22 12 0.96
∆SOFA ≤ 0 (n = 49) 24 (72.7) 16 (72.7) 9 (69.2)
∆SOFA > 0 (n = 19) 9 (27.3) 6 (27.3) 4 (30.8)
Total (n = 68) 33 22 13 0.97
Results are numbers of patients; percentages are given in parentheses. VAP, ventilator-associated pneumonia; PCT, procalcitonin; CRP, C-
reactive protein; SOFA, Sequential Organ Failure Assessment.
Key messages
•  Survival is directly related to decreasing levels of pro-
calcitonin and C-reactive protein in ventilator-associ-
ated pneumonia.Available online http://ccforum.com/content/10/5/R125
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